We are proud to present the Summer edition of our biannual Pharma Report. The report looks at some of the legal developments during the first half of 2018 in the pharmaceutical sector in Norway.
The first half of 2018 has been an eventful six months for legal practitioners in the pharmaceutical sector. There have been important cases on regulatory affairs and intellectual property. We are therefore pleased to present a retrospective view on some of these legal developments.
In this edition of our biannual report, you can read about AstraZeneca’s challenge on the Norwegian Medicines Agency’s decision to subject its blockbuster inhaler medicine to generic substitution. You can also read about several patent cases, including a case where we successfully represented a client who faced a preliminary injunction in connection with a patent on vaginal rings. Furthermore, you can also read about the Norwegian perspective on implementing the treatment for one of the world’s most expensive drugs.
Haavind’s Health and Life Science team continuously and closely monitors developments in Norway relevant to the pharma sector. If you wish to discuss how your business can best meet the legal challenges of this innovative and highly regulated sector, you are always welcome to contact us.
Would you like to receive our newsletters and future reports? Send us an email.